Several biotech-focused venture firms have closed large fundraising rounds, reflecting sustained, though selective, investor interest. Omega Funds announced a $647 million eighth fund, nearly matching prior size, while Australian firm Brandon Capital closed its sixth fund with A$439 million ($290 million), its largest to date. Meanwhile, TCG Labs Soleil raised another $400 million to continue building single-asset biotechs and launched a Shanghai office. These fundraises come amid a market leaning towards supporting fewer companies but with larger investments, emphasizing competitive positioning and capital efficiency.